<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01310647</url>
  </required_header>
  <id_info>
    <org_study_id>2009-018009-26</org_study_id>
    <secondary_id>2009-018009-26</secondary_id>
    <nct_id>NCT01310647</nct_id>
  </id_info>
  <brief_title>Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders</brief_title>
  <acronym>FOLLPRIM</acronym>
  <official_title>Prospective Randomized Controlled Trial of Antral Follicle Priming Prior to IVF-ICSI in Previously Diagnosed Low Responders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effectiveness of testosterone,estradiol and a
      combined treatment with estrogens/progestagens prior to IVF-ICSI in previously diagnosed low
      responder patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During controlled ovarian hyperstimulation (COH), most of the early antral follicles are
      required to grow coordinately. Marked follicular size discrepancies during COH imply that an
      important number of follicles undergo unsatisfactory maturation. It has been proved that
      follicular priming with estradiol during the luteal phase of the cycle prior to COH or
      testosterone treatment during the early follicular phase of the COH cycle may increase the
      amount of oocytes and embryos retrieved. Nevertheless there are no prospective studies
      comparing such approaches. The present study consist of two phases:

      The present study consists of two different phases:

        -  Phase I: (Non randomized) Identification of confirmed low responder patients. Potential
           low responder patients will be subjected to an standardized ovarian hyperstimulation
           protocol

        -  Phase II: (Randomized) those patients, once confirmed as low responders, will be offered
           the opportunity to enter the interventional part of the study, being randomized to three
           different treatment groups: estradiol, testosterone or combined progestagens and
           estrogens prior to the IVF-ICSI cycle. The previous cycle (phase I) will be used as a
           self-control for each patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of MII oocytes retrieved</measure>
    <time_frame>36h after GnRH analogue administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of follicles punctured</measure>
    <time_frame>36h after GnRH analogue administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of oocytes retrieved</measure>
    <time_frame>36h after GnRH analogue administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of viable embryos</measure>
    <time_frame>48h after follicular puncture</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and Follicular hormonal levels (testosterone, androstenedione, estradiol)</measure>
    <time_frame>36h after GnRH analogue administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Granulosa cells genetic expression profile</measure>
    <time_frame>36h after GnRH analogue administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>15 days after embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>15 days after embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>5 weeks after embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Ovarian Diseases</condition>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transdermal testosterone (20µg/day) from day 24 of the previous cycle until day 2 of the ICSI cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CombEq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI
Estradiol valerate 4 mg/day during 10 days, starting the second day of the cycle prior to the ICSI cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle</description>
    <arm_group_label>Testosterone</arm_group_label>
    <other_name>Testopatch, Pierre Fabre Ibérica S.A.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle</description>
    <arm_group_label>Estradiol</arm_group_label>
    <other_name>Alcis 100, Chiesi España</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CombEq</intervention_name>
    <description>(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.
Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle.</description>
    <arm_group_label>CombEq</arm_group_label>
    <other_name>Microdiol, MERCK SHARP &amp; DOHME</other_name>
    <other_name>Meriestra 2mg, Novartis Farmacéutica, S.A.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Phase 1 (Non randomized. The patient must fit the first plus at least other 2
             criteria)

               -  Infertility requiring an IVF/ICSI treatment

               -  Age ≥ 38 years

               -  Basal FSH ≥ 10 mUI/ml (day 3 of the cycle)

               -  Serum AMH ≤ 5 pmol/l

               -  Antral follicular count ≤ 6 (day 3 of the cycle)

          2. Phase 2 (Randomized. The patient must fit at least one criterion regarding the day of
             GNRH analogue administration during the cycle performed in Phase 1)

               -  Less than 4 follicles which mean diameter measuring more than 16mm

               -  Serum estradiol levels ≤ 500 pg/ml

               -  4 MII or less than 4 MII oocytes retrieved

        Exclusion Criteria:

          -  Patients suffering of endometriosis

          -  Patients having progesterone levels ≤ 4 ng/ml (day 21 of the cycle)

          -  Patients having a partner affected by severe oligo/astheno/teratozoospermia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>César Díaz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Fe University Hospital. Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Pellicer, Professor</last_name>
    <role>Study Director</role>
    <affiliation>La Fe University Hospital. Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alicia Marzal, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>La Fe University Hospital. Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>La Fe University Hospital. Department of Obstetrics and Gynecology</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod. 2003 Dec;18(12):2698-703.</citation>
    <PMID>14645194</PMID>
  </reference>
  <reference>
    <citation>Fábregues F, Peñarrubia J, Creus M, Manau D, Casals G, Carmona F, Balasch J. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum Reprod. 2009 Feb;24(2):349-59. doi: 10.1093/humrep/den428. Epub 2008 Dec 3.</citation>
    <PMID>19054777</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2011</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>estradiol</keyword>
  <keyword>testosterone</keyword>
  <keyword>combined oral contraceptive</keyword>
  <keyword>low responders</keyword>
  <keyword>ICSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 26, 2015</submitted>
    <returned>December 30, 2015</returned>
    <submitted>February 14, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

